免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / DOZE Sleep App for Youth With Sleep Disturbance

DOZE Sleep App for Youth With Sleep Disturbance

Study Description
Brief Summary:

Insomnia is a highly prevalent problem among adolescents and young adults (AYAs) with mental health issues. Although evidence-based treatments to quickly address insomnia exist, access to such treatments is limited and there is very little research in AYAs. Furthermore, some of the sleep problems of AYA are unique (e.g., voluntary sleep restriction, circadian phase delay, very poor sleep hygiene), so pediatric and adult programs are not suitable for this age group. This study will test an innovative program that consists of an integrated smart phone application (app) and web self-management system ("DOZE") to help adolescents and young adults sleep better. The first phase of this project, now completed, involved interviewing primary stakeholders of the app (AYAs) to evaluate a low-fidelity prototype of the app and to gather information regarding their opinion about what tools participants would use to improve their health and/or sleep. Using the data from phase I, the investigators have created an app that is acceptable, useful and easy to use while meeting the needs of AYAs experiencing sleep problems. In this study, the investigators will conduct an open trial of the app with 145 AYAs to evaluate usability, acceptability, and sleep and corollary outcomes using a mixed methods design.

The investigators hypothesize:

  1. That participants (AYAs) will find the app satisfactory and credible;
  2. DOZE will effect sleep-related behaviour change;
  3. DOZE will contribute to improvements in energy, mood, and perceived quality of life.

Exploratory analyses will also be conducted to evaluate which aspects of DOZE participants (AYAs) found most helpful.


Condition or disease Intervention/treatment Phase
Insomnia Other: DOZE Sleep App Not Applicable

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 145 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evidence-Based e-Health Solutions for Youth With Mental Illness - Phase II
Estimated Study Start Date : June 2019
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : March 2020
Arms and Interventions
Arm Intervention/treatment
Experimental: DOZE Users
Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
Other: DOZE Sleep App
DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.

Outcome Measures
Primary Outcome Measures :
  1. Treatment Evaluation Questionnaire [ Time Frame: Endpoint (week 4 or later) ]
    A quantitative questionnaire consisting of 5 questions evaluating treatment credibility. Scores range from 5 to 35, with higher scores indicating a more favourable evaluation of treatment.

  2. Acceptability E-Scale [ Time Frame: Endpoint (week 4 or later) ]
    A quantitative questionnaire, created for the purposes of this study, consisting of 6 questions assessing the acceptability of the app (helpfulness, usefulness, understandability, ease of use, enjoyment, and overall satisfaction) using a 5-point Likert scale. Scores range from 5 to 30, with higher scores indicating greater acceptability of the app.

  3. Qualitative Assessment: Post-Test [ Time Frame: Endpoint (week 4 or later) ]
    A qualitative questionnaire, created for the purposes of this study, consisting of 4 open-ended questions to obtain feedback on the app. Because of its qualitative nature, no scores are associated with this outcome; rather, this assessment will be used to receive open-ended feedback from the participants about the aspects of the app that they did and did not like.


Secondary Outcome Measures :
  1. Google Analytics: time spent on each app page [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the time spent by each participant on each page/area of the app. This information will be used qualitatively to understand which aspects of the app were found least/most helpful.

  2. Google Analytics: number of times app logged in [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the number of times each participant logged into the app. Greater adherence to app use (and daily sleep tracking) indicates greater acceptability of the app.

  3. Google Analytics: number of times app used [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the number of times participants used the app. Greater app use indicates greater acceptability of the app. Google Analytics will provide a count of the number of times the app was accessed.

  4. Google Analytics: number of quizzes completed [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the number of quizzes each participant completed. Quizzes are included in the app under the "Tips" heading, and include questions that related to chronotype, difficulty winding down, difficulty getting up, sleep drunkenness, trouble staying awake, and fatigue. Quizzes are an optional feature of the app which are used to provide participants with psychoeducation about these topics and how they relate to symptoms of sleep disturbance.

  5. Sleep diary parameters [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Data extracted from sleep diaries, including variability in bedtime, variability in rise time, total sleep time, total time in bed, sleep onset latency, wake after sleep onset, number of awakenings, naps

  6. Center for Epidemiological Studies Depression Scale-Revised (9 items) [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    Scores range from 0 to 36, with higher scores indicating more severe depressive symptoms.

  7. State-Trait Inventory of Cognitive and Somatic Anxiety [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    This measure includes two scales: a state scale (with scores ranging from 21 to 84) and a trait scale (with scores ranging from 21 to 84). Higher scores on both scales indicate more severe symptoms of anxiety.

  8. Fatigue Severity Scale [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    A total score is computed by summing all of the items (range: 9 to 63) and dividing the score by the number of items to yield an item average. Average scores range from 1 to 7, with higher average scores indicating more impairment due to fatigue.

  9. Cleveland Adolescent Sleepiness Scale [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    Scores range from 0 to 64, with higher scores indicating greater sleepiness.

  10. Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    Assesses health-related quality of life using 8 subscales: vitality, physical functioning, bodily pain, general, health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health. Items in which higher scores indicate better functioning are reverse scored when creating subscale scores. Subscale scores are converted to T scores ranging from 0 to 100, with higher scores indicating worse functioning.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   15 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age between 15 and 24 years
  • Experiencing sleep disturbance

Exclusion Criteria:

  • None
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Olya Bogouslavsky, MPH 4169795000 ext 2185 olya@arts.ryerson.ca
Contact: Nicole E Carmona, BSc 4169795000 ext 2185 nicole.carmona@psych.ryerson.ca

Locations
Layout table for location information
Canada, Ontario
Ryerson University
Toronto, Ontario, Canada, M5B2K3
Contact: Colleen Carney, PhD    416-979-5000 ext 2177    ccarney@ryerson.ca   
Contact: Olya Bogouslavsky, MPH    416-979-5000 ext 2185    olya@ryerson.ca   
Sponsors and Collaborators
Ryerson University
Investigators
Layout table for investigator information
Principal Investigator: Colleen E Carney, PhD Ryerson University
Tracking Information
First Submitted Date  ICMJE May 5, 2019
First Posted Date  ICMJE May 23, 2019
Last Update Posted Date May 23, 2019
Estimated Study Start Date  ICMJE June 2019
Estimated Primary Completion Date February 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 21, 2019)
  • Treatment Evaluation Questionnaire [ Time Frame: Endpoint (week 4 or later) ]
    A quantitative questionnaire consisting of 5 questions evaluating treatment credibility. Scores range from 5 to 35, with higher scores indicating a more favourable evaluation of treatment.
  • Acceptability E-Scale [ Time Frame: Endpoint (week 4 or later) ]
    A quantitative questionnaire, created for the purposes of this study, consisting of 6 questions assessing the acceptability of the app (helpfulness, usefulness, understandability, ease of use, enjoyment, and overall satisfaction) using a 5-point Likert scale. Scores range from 5 to 30, with higher scores indicating greater acceptability of the app.
  • Qualitative Assessment: Post-Test [ Time Frame: Endpoint (week 4 or later) ]
    A qualitative questionnaire, created for the purposes of this study, consisting of 4 open-ended questions to obtain feedback on the app. Because of its qualitative nature, no scores are associated with this outcome; rather, this assessment will be used to receive open-ended feedback from the participants about the aspects of the app that they did and did not like.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: May 21, 2019)
  • Google Analytics: time spent on each app page [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the time spent by each participant on each page/area of the app. This information will be used qualitatively to understand which aspects of the app were found least/most helpful.
  • Google Analytics: number of times app logged in [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the number of times each participant logged into the app. Greater adherence to app use (and daily sleep tracking) indicates greater acceptability of the app.
  • Google Analytics: number of times app used [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the number of times participants used the app. Greater app use indicates greater acceptability of the app. Google Analytics will provide a count of the number of times the app was accessed.
  • Google Analytics: number of quizzes completed [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Google Analytics will be used to track the number of quizzes each participant completed. Quizzes are included in the app under the "Tips" heading, and include questions that related to chronotype, difficulty winding down, difficulty getting up, sleep drunkenness, trouble staying awake, and fatigue. Quizzes are an optional feature of the app which are used to provide participants with psychoeducation about these topics and how they relate to symptoms of sleep disturbance.
  • Sleep diary parameters [ Time Frame: Everyday for duration of study participation (i.e., week 0 to week 4 or later) ]
    Data extracted from sleep diaries, including variability in bedtime, variability in rise time, total sleep time, total time in bed, sleep onset latency, wake after sleep onset, number of awakenings, naps
  • Center for Epidemiological Studies Depression Scale-Revised (9 items) [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    Scores range from 0 to 36, with higher scores indicating more severe depressive symptoms.
  • State-Trait Inventory of Cognitive and Somatic Anxiety [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    This measure includes two scales: a state scale (with scores ranging from 21 to 84) and a trait scale (with scores ranging from 21 to 84). Higher scores on both scales indicate more severe symptoms of anxiety.
  • Fatigue Severity Scale [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    A total score is computed by summing all of the items (range: 9 to 63) and dividing the score by the number of items to yield an item average. Average scores range from 1 to 7, with higher average scores indicating more impairment due to fatigue.
  • Cleveland Adolescent Sleepiness Scale [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    Scores range from 0 to 64, with higher scores indicating greater sleepiness.
  • Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) [ Time Frame: Baseline (week 0) and endpoint (week 4 or later) ]
    Assesses health-related quality of life using 8 subscales: vitality, physical functioning, bodily pain, general, health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health. Items in which higher scores indicate better functioning are reverse scored when creating subscale scores. Subscale scores are converted to T scores ranging from 0 to 100, with higher scores indicating worse functioning.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE DOZE Sleep App for Youth With Sleep Disturbance
Official Title  ICMJE Evidence-Based e-Health Solutions for Youth With Mental Illness - Phase II
Brief Summary

Insomnia is a highly prevalent problem among adolescents and young adults (AYAs) with mental health issues. Although evidence-based treatments to quickly address insomnia exist, access to such treatments is limited and there is very little research in AYAs. Furthermore, some of the sleep problems of AYA are unique (e.g., voluntary sleep restriction, circadian phase delay, very poor sleep hygiene), so pediatric and adult programs are not suitable for this age group. This study will test an innovative program that consists of an integrated smart phone application (app) and web self-management system ("DOZE") to help adolescents and young adults sleep better. The first phase of this project, now completed, involved interviewing primary stakeholders of the app (AYAs) to evaluate a low-fidelity prototype of the app and to gather information regarding their opinion about what tools participants would use to improve their health and/or sleep. Using the data from phase I, the investigators have created an app that is acceptable, useful and easy to use while meeting the needs of AYAs experiencing sleep problems. In this study, the investigators will conduct an open trial of the app with 145 AYAs to evaluate usability, acceptability, and sleep and corollary outcomes using a mixed methods design.

The investigators hypothesize:

  1. That participants (AYAs) will find the app satisfactory and credible;
  2. DOZE will effect sleep-related behaviour change;
  3. DOZE will contribute to improvements in energy, mood, and perceived quality of life.

Exploratory analyses will also be conducted to evaluate which aspects of DOZE participants (AYAs) found most helpful.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Insomnia
Intervention  ICMJE Other: DOZE Sleep App
DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
Study Arms  ICMJE Experimental: DOZE Users
Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
Intervention: Other: DOZE Sleep App
Publications *
  • Gradisar M, Gardner G, Dohnt H. Recent worldwide sleep patterns and problems during adolescence: a review and meta-analysis of age, region, and sleep. Sleep Med. 2011 Feb;12(2):110-8. doi: 10.1016/j.sleep.2010.11.008. Epub 2011 Jan 22. Review.
  • Sivertsen B, Harvey AG, Lundervold AJ, Hysing M. Sleep problems and depression in adolescence: results from a large population-based study of Norwegian adolescents aged 16-18 years. Eur Child Adolesc Psychiatry. 2014 Aug;23(8):681-9. doi: 10.1007/s00787-013-0502-y. Epub 2013 Nov 30.
  • Hicks RA, Fernandez C, Pellegrini RJ. Striking changes in the sleep satisfaction of university students over the last two decades. Percept Mot Skills. 2001 Dec;93(3):660.
  • Yang CM, Wu CH, Hsieh MH, Liu MH, Lu FH. Coping with sleep disturbances among young adults: a survey of first-year college students in Taiwan. Behav Med. 2003 Fall;29(3):133-8.
  • Crowley SJ, Acebo C, Carskadon MA. Sleep, circadian rhythms, and delayed phase in adolescence. Sleep Med. 2007 Sep;8(6):602-12. Epub 2007 Mar 26. Review.
  • Aoki H, Ozeki Y, Yamada N. Hypersensitivity of melatonin suppression in response to light in patients with delayed sleep phase syndrome. Chronobiol Int. 2001 Mar;18(2):263-71.
  • Mindell JA, Kuhn B, Lewin DS, Meltzer LJ, Sadeh A; American Academy of Sleep Medicine. Behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep. 2006 Oct;29(10):1263-76. Review. Erratum in: Sleep. 2006 Nov 1;29(11):1380.
  • Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians. Pediatrics. 2003 May;111(5 Pt 1):e628-35.
  • Stojanovski SD, Rasu RS, Balkrishnan R, Nahata MC. Trends in medication prescribing for pediatric sleep difficulties in US outpatient settings. Sleep. 2007 Aug;30(8):1013-7.
  • Boerner KE, Coulombe JA, Corkum P. Barriers and facilitators of evidence-based practice in pediatric behavioral sleep care: qualitative analysis of the perspectives of health professionals. Behav Sleep Med. 2015;13(1):36-51. doi: 10.1080/15402002.2013.838766. Epub 2013 Dec 23.
  • Clarke G, Harvey AG. The complex role of sleep in adolescent depression. Child Adolesc Psychiatr Clin N Am. 2012 Apr;21(2):385-400. doi: 10.1016/j.chc.2012.01.006. Review.
  • Speth TA, Coulombe JA, Markovich AN, Chambers CT, Godbout R, Gruber R, Hall WA, Reid GJ, Stremler R, Weiss SK, Witmans M, Corkum PV. Barriers, facilitators, and usability of an Internet intervention for children aged 1 to 10 years with insomnia. Translational Issues in Psychological Science 1(1): 16-31, 2015.
  • Espie CA, Kyle SD, Williams C, Ong JC, Douglas NJ, Hames P, Brown JS. A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep. 2012 Jun 1;35(6):769-81. doi: 10.5665/sleep.1872.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: May 21, 2019)
145
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2020
Estimated Primary Completion Date February 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age between 15 and 24 years
  • Experiencing sleep disturbance

Exclusion Criteria:

  • None
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 15 Years to 24 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03960294
Other Study ID Numbers  ICMJE 348431
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Colleen Carney, Ryerson University
Study Sponsor  ICMJE Ryerson University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Colleen E Carney, PhD Ryerson University
PRS Account Ryerson University
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP